Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8671830 | 1.00 | TSHR (0.44) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL8743277 | 1.00 | TSHR (0.44) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL18632072 | 1.00 | TSHR (0.44) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL8743092 | 1.00 | TSHR (0.44) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL11580672 | 0.83 | TSHR (0.61) | TSHRALDH1A1 | |
| SCHEMBL23854647 | 0.67 | TSHR (1.00) | TSHRTHRBALDH1A1DNM1LMNA | |
| Hexadecane SCHEMBL23499901 | 0.67 | TSHR (1.00) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL11854960 | 0.67 | TSHR (1.00) | TSHRTHRBALDH1A1DNM1LMNA | |
| Decane SCHEMBL23499900 | 0.67 | TSHR (1.00) | TSHRTHRBALDH1A1DNM1LMNA | |
| Decane SCHEMBL170135 | 0.67 | TSHR (1.00) | TSHRTHRBALDH1A1DNM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048005-A1 | INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS | MASSACHUSETTS GEN HOSPITAL (US) | 2026-02-19 | — | — | US | claimed |
| US-20260035519-A1 | PROCESS FOR EFFICIENT CROSS-LINKING OF HYALURONIC ACID | Galderma Holding SA (CH) | 2026-02-05 | — | — | US | claimed |
| US-12454602-B2 | Process for efficient cross-linking of hyaluronic acid | Galderma Holding SA (CH) | 2025-10-28 | — | — | US | claimed |
| EP-4590352-A1 | MULTI-COMPONENT HYDROGEL GEL AND USES OF THE SAME | Galderma Holding SA (CH) | 2025-07-30 | — | — | EP | claimed |
| EP-4572752-A1 | INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS | The General Hospital Corporation (US) | 2025-06-25 | — | — | EP | claimed |
| EP-4530308-A1 | MULTI-CROSSLINKED GEL SYSTEM AND PRODUCT THEREOF, PREPARATION METHOD, AND USE | Shanghai Qisheng Biological Preparation Co., Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| EP-4525942-A1 | SYSTEMS AND METHODS FOR IMPROVED STERILE PROCESSING OF BIOLOGICAL MATERIAL | Rosivo LLC (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2025029775-A1 | SYSTEMS AND METHODS FOR IMPROVED STERILE PROCESSING OF BIOLOGICAL MATERIAL | ROSIVO LLC (US) | 2025-02-06 | — | — | WO | claimed |
| EP-4456936-A1 | SOFT TISSUE AUGMENTATION USING INJECTABLE, NEUTRAL PH SOLUBLE COLLAGEN-GLYCOSAMINOGLYCAN COMPOSITIONS | Shanghai Qisheng Biological Preparation Co., Ltd. (CN) | 2024-11-06 | — | — | EP | claimed |
| WO-2024212266-A1 | MULTI-CROSSLINKED GEL SYSTEM AND PRODUCT THEREOF, PREPARATION METHOD, AND USE | 上海其胜生物制剂有限公司 | 2024-10-17 | — | — | WO | claimed |
| WO-2004106555-A2 | HIGH-THROUGHPUT METHODS OF SCREENING DNA FOR DELETIONS AND OTHER MUTATIONS | DOW AGROSCIENCES LLC (US) | 2004-12-09 | — | — | WO | claimed |
| US-6762019-B2 | Use in activated slides for making microarrays of nucleic acids; monomers with pendant epoxy groups to immobilize biological targets, diluent monomers or polymers, and monomers having a photoreactive group to surface treat the substrate | SURMODICS, INC. | 2004-07-13 | — | — | US | claimed |
| US-20040053236-A1 | Reverse genetic strategy for identifying functional mutations in genes of known sequences | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-18 | — | — | US | claimed |
| EP-1139911-A4 | METHOD FOR TISSUE FIXATION | AV HEALING LLC (US) | 2003-07-23 | — | — | EP | claimed |
| WO-2001075167-A1 | REVERSE GENETIC STRATEGY FOR IDENTIFYING FUNCTIONAL MUTATIONS IN GENES OF KNOWN SEQUENCE | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2001-10-11 | — | — | WO | claimed |
| EP-1139911-A1 | METHOD FOR TISSUE FIXATION USING EPOXIDES | AV Healing LLC (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035374-A1 | METHOD FOR TISSUE FIXATION | AV HEALING LLC (US) | 2000-06-22 | — | — | WO | claimed |
| US-5670052-A | CROSSLINKED MEMBRANE | EXXON RESEARCH & ENGINEERING COMPANY (US) | 1997-09-23 | — | — | US | claimed |
| US-5550199-A | MEMBRANES | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1996-08-27 | — | — | US | claimed |
| EP-0097005-B1 | THIOETHER-MODIFIED SEALANT COMPOSITIONS AND INSULATED GLASS ARTICLES SEALED THEREWITH | MORTON THIOKOL, INC. (US) | 1986-10-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048005-A1 | INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS | CD44, FECH, HSF1 | TSHR 563/4885THRB 2197/4885ALDH1A1 300/4885 |
| US-20260035519-A1 | PROCESS FOR EFFICIENT CROSS-LINKING OF HYALURONIC ACID | CD44, TRHDE, HAO2 | TSHR 1401/4885THRB 1377/4885ALDH1A1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.